Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316589 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 581
- Enrollment target
NCT00316589: Completed Phase 2 study, sponsored by Bavarian Nordic.
NCT00316589 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 581 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (337% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00316589, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 581 participants
- Enrollment target
Study Summary
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations
Primary Outcome
Incidence, relationship and intensity of any Serious Adverse Event (SAE)
Interventions
- BIOLOGICAL IMVAMUNE (MVA-BN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00316589 record still lists
NCT00316589 is an interventional study that assigns participants to a tested intervention. The registered 581 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (337% higher).
The record links to 0 conditions, and to 1 intervention - of which IMVAMUNE (MVA-BN) is the first listed.
NCT00316589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00316589 about?
NCT00316589 is a clinical study titled "Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients". The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations
What is the current status of trial NCT00316589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 581 participants. The study started on 2006-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00316589?
The interventions under investigation include: IMVAMUNE (MVA-BN) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00316589?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00316589's enrollment target sits among peer trials
581 58th of 2000 higher than 1,943 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia